Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX restores the missing component of the intrinsic coagulation pathway. Once infused, it binds to activated factor VIII on phospholipid surfaces, participates in the activation of factor X, and ultimately leads to thrombin generation and fibrin clot formation, correcting the bleeding tendency.

The dose of Immunine is individualized. A qualified prescriber determines the amount and frequency based on the patient’s factor IX activity level, severity of bleeding, body weight, and clinical response. Dosing is calculated to achieve target plasma factor IX levels appropriate for the specific clinical situation.

Safety data for Immunine in pregnancy and lactation are limited. Because factor IX replacement is often required for women with Hemophilia B, the benefits and potential risks should be evaluated by the treating physician. The prescriber should discuss any concerns and consider the most current clinical guidelines.

To request Immunine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Immunine is a recombinant human factor IX concentrate similar in efficacy to other licensed factor IX products. Differences may lie in manufacturing processes, stabilizers, and storage requirements. Clinicians typically choose a product based on clinical experience, patient tolerance, availability, and cost considerations.

Immunine must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. If temperature excursions occur, the product should be inspected for any changes before use.

Immunine is given by intravenous infusion. The infusion rate and volume are determined by the prescriber based on the calculated dose. Administration should be performed in a clinical setting with appropriate monitoring for infusion‑related reactions and under aseptic conditions.

The most serious risks include the development of neutralizing antibodies (inhibitors) against factor IX, which can reduce efficacy, and rare but severe hypersensitivity reactions such as anaphylaxis. Thrombotic complications may also occur, especially if dosing exceeds target plasma levels.

Immunine is contraindicated in patients with known hypersensitivity to any component of the formulation. It should also be avoided in individuals who have previously developed inhibitors to factor IX unless a specialist determines that benefits outweigh risks.